Our first challenge was convincing our health science colleagues that nurses should be conducting a clinical trial, because prescribing is not usually considered a nursing function. Hence, pharmaceutical clinical trials are not nursing research. Our stance was that nurses might well be asked to recommend or comment on alternative therapies and that they were capable of generating the empirical evidence. Drug trials traditionally have been conducted by physicians or by pharmacological investigators and supported by drug companies.
There is no such support, however, for alternative therapies. EVA is a good example of this dilemma.
Unlike the established pharmaceutical industries, the elk velvet industry in North America is in a fledgling stage, with few dollars available for research and development. Therefore, initial basic research into alternative therapies is expected to be funded by other sources. Evidence is needed, and who better to gather such evidence than nurses? Therefore, our research team was headed by nurses as coprincipal investigators and assisted by a physician and a statistician.
We next encountered difficulties in obtaining ethics approval for our study. The first problem was that the study was a clinical trial, and the ethics committee assigned to review it was unfamiliar with the intricacies of this type of design. Concerns then were raised about the standardization of a dose of EVA. This was particularly problematic, because EVA is a naturally occurring substance, and all we could guarantee was that each capsule prepared for the study would contain an equal amount of EVA (i.e., 200 milligrams). We could not say that each capsule would contain exactly the same amount of active ingredients (e.g., Is there the same amount of vitamin C in every orange?). The proportionate constituents of elk antler are determined, in part, by what the animal eats and the animal's state of general health. Basic research has detailed the chemical composition of EVA, but what the "active ingredients" are is unknown. Even if we were able to standardize constituents, we would not know what particular combination of ingredients to choose. Such will be the case with most studies of ingestible alternative products, because most are naturally occurring, not artificially produced under controlled conditions. We eventually satisfied the committee that standardizing the number of milligrams in each capsule would be sufficient control.
Another problem was that we planned to study patients whose RA symptoms were uncontrolled because EVA is unproven as a therapeutic modality, and it would be unethical to remove patients from their prescribed regimens. Therefore, before undertaking a large controlled trial we had to establish that there would be no adverse effects from taking EVA concurrently with standard RA medications, the major purpose of our pilot study. Alternative therapies do not normally come within the parameters of the traditional public funding bureaucracies. Therefore, the processes of review focus on safety related to new drugs and new therapies. We were not truly concerned about safety because EVA has been in use for centuries, and there have been no reported ill effects, so we were comfortable asking for funding from the elk velvet industry. This was willingly supplied, but we then had to face questions from the media about "arms length" funding and possible bias in our study. Our response was that this was no different from new drug studies funded by drug companies. Control of bias was inherent in the double-blind placebo-controlled design.
Our second challenge was the skepticism that arises within the community of health scientists when one mentions alternative therapies. We faced laughter bordering on ridicule from our colleagues for our willingness to examine something as peculiar as "ground up elk horns."
Response from the public was quite different, however. Once we started soliciting participants, word about our plans became public and we were besieged with calls from the media, including television, newspapers, and popular magazines. Following a television interview we received close to 300 telephone calls from RA patients eager to participate in the study! That was a challenge in itself, and it reinforced the notion of selfmedication among this group of chronic pain sufferers.
These are just some of the kinds of problems one can expect when studying alternative therapies. We believe that this is an important avenue for nursing research, and our purpose in describing our experiences has been to illuminate some of the roadblocks. Our assumption is that if one is prepared for the kinds of concerns that might arise, one will be more successful in dealing with them. The results from the pilot project are very promising and suggest that EVA may indeed have positive effects on RA. Our next step is to conduct the larger trial. There are difficulties in carrying out studies that focus on alternative therapies, but we are excited about the prospects of contributing to the knowledge base about treatment for RA. We hope other nurses will be similarly intrigued and undaunted by the challenges of conducting research with alternative therapies.
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